Nordicus Partners Corp SEC 10-Q Report

Nordicus Partners Corp, a business accelerator and holding company for Nordic life sciences companies, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational developments, reflecting its strategic focus on advancing Nordic innovation in the American market. Financial Highlights Revenue: $0, reflecting a decrease from $2,500 in the same period last year, indicating a lack of sales activity during the reporting period.Loss from Operations: $(1,122,172), compared to $(1,265,310) in the prior year, showing a slight improvement in operational efficiency.Net Loss: $(1,247,524), compared to $(1,545,311) in the previous year, indicating a reduction in overall losses.Net Loss Per Share: $(0.07), compared to $(0.13) in the prior year, reflecting a decrease in loss per share due to an increase in the number of shares outstanding. Business Highlights Organizational History: Nordicus Partners Corporation, originally founded in 1993, has undergone several transformations, including a name change to Nordicus Partners Corporation in May 2023. The company has shifted its focus to becoming a business accelerator and holding company for Nordic life sciences companies aiming to enter the American market.Portfolio Companies: Nordicus currently manages three preclinical biotechnology companies: Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. These companies are focused on developing innovative treatments for aggressive periodontitis, oral leukoplakia, and psoriasis, respectively.Orocidin A/S Developments: Orocidin has completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, showing promising results for its lead product, QR-01, in treating periodontitis.Bio-Convert A/S Developments: Bio-Convert received positive feedback from the Danish Medicines Agency regarding its lead candidate, QR-02, for treating oral leukoplakia, paving the way for a First in Human trial.NoviThera ApS Formation: In October 2025, Nordicus formed NoviThera to develop a novel Monoclonal antibody for psoriasis treatment, with intellectual property contributed by Alteral Therapeutics.Future Outlook: Nordicus aims to advance its portfolio companies through Phase I clinical trials, with potential exit strategies including sales, mergers, strategic partnerships, or IPOs. The company is focused on leveraging Nordic innovation and U.S. operational expertise to create value in high-growth markets with unmet medical needs.SEC Filing: Nordicus Partners Corp [ NORD ] - 10-Q - Feb. 13, 2026